RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target

Autores
Amorós Morales, Leslie Cinthya; Gómez Bergna, Santiago Manuel; Marchesini, Abril; Scalise, María Luján; Gonzalez, Nazareno; Ferrelli, María Leticia; Candolfi, Marianela; Romanowski, Víctor; Pidre, Matías Luis
Año de publicación
2025
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Diffuse gliomas (DGs) are malignant primary brain tumors originating from glial cells. This study aimed to investigate the role of Receptor-interacting protein kinase 1 (RIPK1) in DG pathology. The RIPK1 mRNA expression was analyzed in DG databases from The Cancer Genome Atlas (TCGA) containing clinical, genomic, and transcriptomic information from 670 patients. Transcriptomic studies were carried out using USC Xena and R, while in vitro assays were performed with the glioblastoma human cell line U251 and the commercial RIPK1 inhibitor GSK2982772. The results showed that high RIPK1 expression was linked to a lower survival probability in patients. Additionally, the RIPK1 expression was higher in the wtIDH samples compared to that in the mIDH samples. Significant differences in the expression of genes related to cellular dedifferentiation, proinflammatory cell death pathways, and tumor-infiltrating immune cells were found between high- and low-RIPK1 expression groups. To further characterize the role of RIPK1 in DG, the effects of the RIPK1 inhibitor were evaluated, alone or combined with cisplatin, on glioblastoma cell proliferation and apoptosis. The combined treatments effectively reduced cell proliferation and increased apoptosis. The overexpression of RIPK1 was associated with a poor prognosis for DG, suggesting that RIPK1 plays a critical role in glioma pathogenesis and should be considered in therapeutic decision-making.
Instituto de Biotecnología y Biología Molecular
Materia
Biología
Química
RIPK1
diffuse gliomas
proinflammatory cell death
cisplatin
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/181710

id SEDICI_1974590b03511f0452f61e86709123f1
oai_identifier_str oai:sedici.unlp.edu.ar:10915/181710
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic TargetAmorós Morales, Leslie CinthyaGómez Bergna, Santiago ManuelMarchesini, AbrilScalise, María LujánGonzalez, NazarenoFerrelli, María LeticiaCandolfi, MarianelaRomanowski, VíctorPidre, Matías LuisBiologíaQuímicaRIPK1diffuse gliomasproinflammatory cell deathcisplatinDiffuse gliomas (DGs) are malignant primary brain tumors originating from glial cells. This study aimed to investigate the role of Receptor-interacting protein kinase 1 (RIPK1) in DG pathology. The RIPK1 mRNA expression was analyzed in DG databases from The Cancer Genome Atlas (TCGA) containing clinical, genomic, and transcriptomic information from 670 patients. Transcriptomic studies were carried out using USC Xena and R, while in vitro assays were performed with the glioblastoma human cell line U251 and the commercial RIPK1 inhibitor GSK2982772. The results showed that high RIPK1 expression was linked to a lower survival probability in patients. Additionally, the RIPK1 expression was higher in the wtIDH samples compared to that in the mIDH samples. Significant differences in the expression of genes related to cellular dedifferentiation, proinflammatory cell death pathways, and tumor-infiltrating immune cells were found between high- and low-RIPK1 expression groups. To further characterize the role of RIPK1 in DG, the effects of the RIPK1 inhibitor were evaluated, alone or combined with cisplatin, on glioblastoma cell proliferation and apoptosis. The combined treatments effectively reduced cell proliferation and increased apoptosis. The overexpression of RIPK1 was associated with a poor prognosis for DG, suggesting that RIPK1 plays a critical role in glioma pathogenesis and should be considered in therapeutic decision-making.Instituto de Biotecnología y Biología Molecular2025-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/181710enginfo:eu-repo/semantics/altIdentifier/issn/1422-0067info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms26125555info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:49:37Zoai:sedici.unlp.edu.ar:10915/181710Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:49:37.965SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
title RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
spellingShingle RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
Amorós Morales, Leslie Cinthya
Biología
Química
RIPK1
diffuse gliomas
proinflammatory cell death
cisplatin
title_short RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
title_full RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
title_fullStr RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
title_full_unstemmed RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
title_sort RIPK1 in Diffuse Glioma Pathology: From Prognosis Marker to Potential Therapeutic Target
dc.creator.none.fl_str_mv Amorós Morales, Leslie Cinthya
Gómez Bergna, Santiago Manuel
Marchesini, Abril
Scalise, María Luján
Gonzalez, Nazareno
Ferrelli, María Leticia
Candolfi, Marianela
Romanowski, Víctor
Pidre, Matías Luis
author Amorós Morales, Leslie Cinthya
author_facet Amorós Morales, Leslie Cinthya
Gómez Bergna, Santiago Manuel
Marchesini, Abril
Scalise, María Luján
Gonzalez, Nazareno
Ferrelli, María Leticia
Candolfi, Marianela
Romanowski, Víctor
Pidre, Matías Luis
author_role author
author2 Gómez Bergna, Santiago Manuel
Marchesini, Abril
Scalise, María Luján
Gonzalez, Nazareno
Ferrelli, María Leticia
Candolfi, Marianela
Romanowski, Víctor
Pidre, Matías Luis
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Biología
Química
RIPK1
diffuse gliomas
proinflammatory cell death
cisplatin
topic Biología
Química
RIPK1
diffuse gliomas
proinflammatory cell death
cisplatin
dc.description.none.fl_txt_mv Diffuse gliomas (DGs) are malignant primary brain tumors originating from glial cells. This study aimed to investigate the role of Receptor-interacting protein kinase 1 (RIPK1) in DG pathology. The RIPK1 mRNA expression was analyzed in DG databases from The Cancer Genome Atlas (TCGA) containing clinical, genomic, and transcriptomic information from 670 patients. Transcriptomic studies were carried out using USC Xena and R, while in vitro assays were performed with the glioblastoma human cell line U251 and the commercial RIPK1 inhibitor GSK2982772. The results showed that high RIPK1 expression was linked to a lower survival probability in patients. Additionally, the RIPK1 expression was higher in the wtIDH samples compared to that in the mIDH samples. Significant differences in the expression of genes related to cellular dedifferentiation, proinflammatory cell death pathways, and tumor-infiltrating immune cells were found between high- and low-RIPK1 expression groups. To further characterize the role of RIPK1 in DG, the effects of the RIPK1 inhibitor were evaluated, alone or combined with cisplatin, on glioblastoma cell proliferation and apoptosis. The combined treatments effectively reduced cell proliferation and increased apoptosis. The overexpression of RIPK1 was associated with a poor prognosis for DG, suggesting that RIPK1 plays a critical role in glioma pathogenesis and should be considered in therapeutic decision-making.
Instituto de Biotecnología y Biología Molecular
description Diffuse gliomas (DGs) are malignant primary brain tumors originating from glial cells. This study aimed to investigate the role of Receptor-interacting protein kinase 1 (RIPK1) in DG pathology. The RIPK1 mRNA expression was analyzed in DG databases from The Cancer Genome Atlas (TCGA) containing clinical, genomic, and transcriptomic information from 670 patients. Transcriptomic studies were carried out using USC Xena and R, while in vitro assays were performed with the glioblastoma human cell line U251 and the commercial RIPK1 inhibitor GSK2982772. The results showed that high RIPK1 expression was linked to a lower survival probability in patients. Additionally, the RIPK1 expression was higher in the wtIDH samples compared to that in the mIDH samples. Significant differences in the expression of genes related to cellular dedifferentiation, proinflammatory cell death pathways, and tumor-infiltrating immune cells were found between high- and low-RIPK1 expression groups. To further characterize the role of RIPK1 in DG, the effects of the RIPK1 inhibitor were evaluated, alone or combined with cisplatin, on glioblastoma cell proliferation and apoptosis. The combined treatments effectively reduced cell proliferation and increased apoptosis. The overexpression of RIPK1 was associated with a poor prognosis for DG, suggesting that RIPK1 plays a critical role in glioma pathogenesis and should be considered in therapeutic decision-making.
publishDate 2025
dc.date.none.fl_str_mv 2025-06
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/181710
url http://sedici.unlp.edu.ar/handle/10915/181710
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1422-0067
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms26125555
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616356345937920
score 13.070432